Articles related to OBESITY/WEIGHT MANAGEMENT

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

Several recent studies link daily avocado consumption to lower dietary glycemic load, reduced diabetes risk in women, and modest blood pressure improvements in prediabetes patients, though small sample sizes and short follow-up periods limit the conclusions.

A new analytical framework applied to 30,000+ parent-child trios found that uninherited parental genes shape children’s height, BMI, and academic performance to a degree approaching the influence of children’s own DNA.

Post-hoc analyses of the ATTAIN-1 and ATTAIN-2 trials found that oral orforglipron at maximum dose produced significant weight reductions across all menopausal stages in women with obesity, with and without type 2 diabetes, at 72 weeks.

Four major societies jointly published the first multidisciplinary guideline for cardiovascular-kidney-metabolic syndrome, introducing a standardized staging system and unified treatment framework across cardiology, nephrology, endocrinology, and primary care.

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.